<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218384</url>
  </required_header>
  <id_info>
    <org_study_id>17-00444</org_study_id>
    <nct_id>NCT03218384</nct_id>
  </id_info>
  <brief_title>Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency</brief_title>
  <official_title>Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand how body levels of iron affect the ability
      to exercise in patients with heart failure.

      Heart failure is a condition in which abnormal pumping action of the heart reduces the flow
      of blood to the body. Patients with heart failure may feel shortness of breath or leg fatigue
      when they exercise. Iron is an essential nutrient in the diet. In heart failure patients, low
      body levels of iron might increase shortness of breath and fatigue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this prospective, double blind parallel group randomized study is to compare
      the effects of ferric carboxymaltose vs. placebo on skeletal muscle mitochondrial oxidative
      capacity, submaximal exercise tolerance, and health-related quality of life in non-anemic
      Heart Failure (HF) patients with functional iron deficiency.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of ferric carboxymaltose 750 mg vs. placebo on change in skeletal muscle mitochondrial oxidative capacity</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Post-exercise phosphocreatine recovery time measured non-invasively with 31P-magnetic resonance spectroscopy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk test distance from baseline to 4 weeks</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Used in the assessment of patients with a variety of cardiopulmonary diseases including pulmonary arterial hypertension (PAH). ... It simply measures the distance that a patient can walk on a flat, hard surface in a period of 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kansas City Cardiomyopathy Questionnaire score from baseline to 4 weeks</measure>
    <time_frame>4 Weeks</time_frame>
    <description>self-administered, 23-item questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose</intervention_name>
    <description>750 MG Iron Per 15 ML Injectable Solution</description>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
    <other_name>Injectafer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic NYHA Class II-III heart failure &gt;3 months

          -  Guideline-recommended heart failure treatment for &gt; 3 months

          -  Hemoglobin &gt;13 g/dl for men and &gt;12 g/dl for women

          -  Functional iron deficiency (defined as serum ferritin level &lt;100 ng/ml or between 100
             and 299 ng/ml with transferrin saturation &lt;20%)

          -  Left ventricular ejection fraction &lt;40%, or left ventricular ejection fraction â‰¥40%
             with left atrial enlargement (left atrial volume index &gt;28 ml/m2) and/or left
             ventricular hypertrophy (left ventricular mass index &gt;95 g/m2 (women) or &gt;115 g/m2
             (men) determined by echocardiogram within last 24 months.

          -  Able and willing to provide written informed consent

        Exclusion Criteria:

          -  Presence of implantable defibrillator, permanent pacemaker, other metal implant not
             compatible with 3TMRS/MRI, or other contraindication to 3T MRS/MRI procedures

          -  Heart failure due to infiltrative cardiomyopathy, restrictive cardiomyopathy, or
             hypertrophic cardiomyopathy

          -  Weight &lt;50 kg or &gt;120 kg

          -  Coronary or cerebral atherothrombotic events in the past 6 months

          -  Hospitalization of emergency room visit for heart failure within past 3 months

          -  ICD shock in last 3 months

          -  Known peripheral artery disease or ankle-brachial index &lt;0.9 at screening visit

          -  Exercise primarily limited by angina, lung disease or neuromuscular disease

          -  Systolic blood pressure &lt;100 or &gt;160 mmHg

          -  Heart rate &lt;50 or &gt;110 min-1

          -  Estimated glomerular filtration rate &lt;30 ml/min

          -  Liver function tests &gt;3 times upper limit of normal

          -  Serum phosphate below normal limit

          -  Pregnant or breast-feeding women

          -  Women of child-bearing potential unwilling to use recommended contraception methods
             during the study

          -  Treatment with oral iron supplements (except multivitamins) in past year

          -  Treatment with intravenous iron in past year

          -  Treatment with erythropoiesis stimulating agents in the past year

          -  Known intolerance of intravenous iron

          -  History of anaphylaxis

          -  Participation in another clinical trial within last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stanley Cobos</last_name>
    <phone>646 501 2897</phone>
    <email>stanley.cobos@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Cobos</last_name>
      <phone>646-501-2897</phone>
      <email>stanley.cobos@nyumc.com</email>
    </contact>
    <investigator>
      <last_name>Stuart Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Injectafer</keyword>
  <keyword>ferric carboxymaltose</keyword>
  <keyword>Supplemental Iron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

